Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational study

Abstract Background Vedolizumab (VDZ), a gut-selective anti-lymphocyte trafficking integrin antibody, is effective in treating patients with moderately to severely active Crohn’s disease (CD). In this study, we examined the real-world effectiveness and safety of induction therapy using VDZ alone or...

Full description

Bibliographic Details

Published in:	BMC Gastroenterology
Main Authors:	Roni Weisshof, Stephan R. Vavricka, Lieven Pouillon, Fiona Braegger, Montserrat Roset, Nawal Bent-Ennakhil, Marc Ferrante
Format:	Article
Language:	English
Published:	BMC 2023-11-01
Subjects:	Budesonide Crohn’s disease Moderately to severely active crohn’s disease Vedolizumab
Online Access:	https://doi.org/10.1186/s12876-023-03032-7